{"id":"W2792200490","doi":"10.1111/bjd.16426","title":"Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)","year":2018,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen's University; Probity Medical Research; Dalhousie University","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Dosing; Psoriasis; Plaque psoriasis; Adverse effect; Psoriasis Area and Severity Index; Randomized controlled trial; Internal medicine; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003821362,0.001166633,0.001998484,0.0002637782,0.000446196,0.001117485,0.0007062222,0.001199212,0.003518136],"category_scores_gemma":[0.002229959,0.0006574741,0.001811147,0.0003102299,0.001021421,0.0007936266,0.0003743205,0.002906327,0.0006704674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006583312,"about_ca_system_score_gemma":0.00131673,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003472806,"about_ca_topic_score_gemma":0.0006670274,"domain_scores_codex":[0.9988244,0.0006584148,0.00007560502,0.0002216504,0.00009001947,0.0001298213],"domain_scores_gemma":[0.9986632,0.0003180786,0.0003687972,0.0001530542,0.00006839632,0.0004283938],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9532862,0.01172675,0.001748368,0.0002850028,0.0006477744,0.00003510912,0.00009385854,0.0004064846,0.006453751,0.00007145116,0.000727265,0.02451791],"study_design_scores_gemma":[0.8927788,0.1020815,0.003679042,0.00001660978,0.000218427,0.00004054635,0.00001082233,0.0003740465,0.000455539,0.00006317263,0.0002713736,0.00001031249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945722,0.00143928,0.0004554666,0.0003500261,0.0001413399,0.001858858,0.0002868751,0.0000639926,0.0008319329],"genre_scores_gemma":[0.9937586,0.0007589136,0.001205092,0.0003992163,0.0002160084,0.002411542,0.0004596442,0.00001660271,0.0007743507],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003821362,"threshold_uncertainty_score":0.02020949,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008463195056420257,"score_gpt":0.2356017949971449,"score_spread":0.2271385999407246,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}